THERAPEUTIC METHODS USING VADADUSTAT
This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1), including methods suitable for conversion, correction, and maintenance therapy for patients. For example, methods described herein are durable, with efficacy observed for 24-52 weeks. Methods described herein can be particularly beneficial for patients converting from a previous anemia treatment comprising administration of an erythropoietin stimulating agent (ESA) such as darbepoetin alfa (DA), CKD patients on dialysis (e.g., peritoneal dialysis or hemodialysis), or CKD patients having certain hemoglobin (Hb) levels.
1 . A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks.
2 . A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the hemoglobin levels are increased to about 10.0-13.0 g/dL from a baseline hemoglobin level in the patient.
3 . A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the hemoglobin levels are maintained or controlled at about 10.0-13.0 g/dL.
4 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks.
5 .- 12 . (canceled)
13 . The method of any claim 1 , wherein the dose of Compound 1 or a pharmaceutically acceptable salt thereof is administered to the patient for at least about 40, 44, 48, or 52 weeks.
14 .- 31 . (canceled)
31 . The method of claim 1 , wherein the patient has non-dialysis dependent chronic kidney disease (NDD-CKD).
32 . The method of claim 1 , wherein the patient has dialysis-dependent chronic kidney disease (DD-CKD).
33 . The method of claim 1 , wherein the patient has been previously treated with an erythropoiesis stimulating agent (ESA).
34 . The method of claim 33 , wherein the patient has been previously treated with an erythropoiesis stimulating agent (ESA) within about six or eight weeks prior to or during a screening period before administering a dose of Compound 1.
35 .- 38 . (canceled)
39 . The method of claim 33 , wherein the erythropoiesis stimulating agent is epoetin, darbepoetin alfa (DA), or methoxy polyethylene glycol-epoetin beta (epoetin beta pegol).
40 .- 59 . (canceled)
60 . The method of claim 1 , wherein the dose comprises about 150, 300, 450, or 600 mg of Compound 1 administered once daily.
61 .- 83 . (canceled)
84 . The method of claim 2 , wherein the hemoglobin levels are increased to about 10.0-12.0, 10.0-11.0, or 11.0-13.0 g/dL.
85 .- 96 . (canceled)
97 . The method of claim 3 , wherein the hemoglobin levels are maintained or controlled at about 10.0-13.0, 10.0-12.0, 11.0-13.0, or 10.0-11.0 g/dL.
98 .- 109 . (canceled)
110 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.
111 .- 115 . (canceled)
116 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.
117 .- 120 . (canceled)
121 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.
122 .- 124 . (canceled)
125 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof,
wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥100 ng/mL and/or a transferrin saturation (TSAT) of ≥20%, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.
126 .- 127 . (canceled)
128 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, obtaining the patient's hemoglobin (Hb) level, and adjusting the dose by about 150 mg of Compound 1 if the patient's hemoglobin (Hb) level is <10.0 g/dL or >11.5 g/dL or <10.0 g/dL or >12.5 g/dL.
129 .- 147 . (canceled)
148 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA).
149 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein
the patient previously has been treated with an erythropoiesis stimulating agent (ESA).
150 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the patient previously has been treated with an erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg, and wherein the dose is administered once daily.
151 .- 152 . (canceled)
153 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.
154 .- 155 . (canceled)
156 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA).
157 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.
158 .- 159 . (canceled)
160 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, wherein the patient has been previously treated with an erythropoiesis stimulating agent (ESA), and
wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL.
161 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof,
wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.
162 .- 163 . (canceled)
164 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof,
wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), and wherein the patient has a serum ferritin level of about ≥100 ng/mL and/or a transferrin saturation (TSAT) of ≥20%.
165 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof,
wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), and wherein the patient has a serum ferritin level of about ≥100 ng/mL and/or a transferrin saturation (TSAT) of ≥20%, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.
166 .- 185 . (canceled)
186 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, wherein
the patient previously has been treated with an erythropoiesis stimulating agent (ESA), and
the initial dose of Compound 1 is selected based on the ESA previously received by the patient, the dosage amount of an ESA previously received by the patient, the patient's hemoglobin (Hgb) levels, and/or the dialysis status of the patient.
187 . The method of claim 1 , comprising orally administering Compound 1,
or a pharmaceutically acceptable salt thereof, wherein
the patient previously has been treated with an erythropoiesis stimulating agent (ESA), and
the patient receives an increase in the dose of Compound 1 within about six weeks after commencing treatment with Compound 1 based on the ESA previously received by the patient, the dosage amount of an ESA previously received by the patient, the patient's hemoglobin (Hgb) levels, and/or the dialysis status of the patient.